MolecularHealth Continues to Grow Management Team with New Chief Commercial Officer Laura Housman joins MolecularHealth’s executive leadership, bringing expertise in strategic marketing and product management Business Wire THE WOODLANDS, Texas -- October 8, 2013 As MolecularHealth moves towards the commercialization of its automated genetic diagnostic platform for cancer care in the first quarter of 2014, the company announced that it has hired Laura Housman to serve as its chief commercial officer. This new hire follows the recent announcement of five key members of the company’s executive team, veterans of US Oncology and Oncopath Laboratory. Housman comes to MolecularHealth with more than 20 years of marketing and sales experience, largely focused in the healthcare and biotech industries. Most recently, she served as Vice President of Global Market Access, Pricing and Health Economics at Novartis Pharmaceuticals’ Molecular Diagnostics (MDx) and Genoptix. She earned both her Master of Business Administration and Master of Public Health degrees from Boston University. “Laura has an impressive track record of introducing healthcare products and services to the market. Her experience at Novartis MDx, Genoptix and Genzyme Genetics gives her great insight into the molecular diagnostics space, which will be essential as we bring MolecularHealth’s platform to market in 2014,” said Lloyd Everson, M.D., CEO of MolecularHealth. “Laura’s background made her a perfect addition to the executive team and we’re thrilled to have her on board.” “After having worked in the molecular diagnostics industry for years and viewing it from multiple angles, I truly believe the notion of having analytics as the engine to drive decision making for doctors and patients is key,” said Laura Housman. “There is a high unmet patient need, and I’m excited to come on board at such a formative time and be given the chance to shape this offering and help the MolecularHealth team meet that need.” After eight years of development by a multidisciplinary team of doctors, scientists and IT experts in Heidelberg, Germany, MolecularHealth is preparing for the commercial launch of its genetic diagnostic platform. The company, backed by Dietmar Hopp, co-founder and former chairman and CEO of SAP, offers an end-to-end service that walks patients and their healthcare providers through the molecular diagnostic process—collecting tumor samples, analyzing the samples, and interpreting the results using a unique analytics platform—all to generate safer and more targeted cancer treatment choices. As part of its offering, MolecularHealth will provide patients, oncologists and pathologists with complete logistical support and help navigating insurance reimbursement for recommended treatments. ABOUT MOLECULARHEALTH MolecularHealth delivers on the promise of personalized, precision medicine. By using advanced proprietary information technologies to sift through terabytes of genetic and molecular test findings in a fraction of the time needed for current manual analysis, MolecularHealth provides doctors and patients with faster, more accurate insights into the role genes play in the progression and treatment of an individual’s cancer. Eight years in development by a multidisciplinary team of doctors, scientists and IT experts, MolecularHealth works in partnership with some of the world’s leading healthcare and information technology companies, including the University of Texas MD Anderson Cancer Center, SAP AG, and the U.S. Food and Drug Administration (FDA). The company has headquarters in The Woodlands, Texas; Basel, Switzerland; and Heidelberg, Germany. Visitwww.molecularhealth.comfor more information. Contact: Gregory FCA Jessica Attanasio Associate Vice President 610-228-2112 Jessica@GregoryFCA.com
MolecularHealth Continues to Grow Management Team with New Chief Commercial Officer
Press spacebar to pause and continue. Press esc to stop.